Skip to main content

Security report for biogen.sk

Biogen Slovakia s.r.o. · Healthcare · Slovakia

Medium risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

70/100

Risk levelMedium

0–100, higher is better. How it is calculated

Biogen Slovakia s.r.o. is a subsidiary of the global biotechnology leader Biogen Inc., specializing in innovative therapies for neurological, neuropsychiatric, immunological, and rare diseases. The website reflects a professional corporate presence localized for Slovakia, emphasizing Biogen's commitment to science-driven healthcare innovation. The digital infrastructure is built on Adobe Experience Manager CMS, leveraging modern JavaScript libraries and integrated with Cookiebot for GDPR-compliant cookie management. Analytics and marketing tools include Google Analytics and Google Tag Manager, supporting moderate user tracking with privacy considerations. Security posture is strong with HTTPS enforcement and secure cookie practices, though additional security headers and explicit incident response policies could enhance trust. Overall, the site demonstrates a mature digital presence aligned with corporate standards and regulatory compliance.

Scanned

This is an earlier scan of biogen.sk. View the latest report

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • Critical

      Unable to retrieve SSL certificate

      Could not establish secure connection to retrieve certificate information

      What to do: Check if the server is accessible and SSL/TLS is properly configured

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.sk

This scan found 13 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
0
Security headers
95
Email security
60
DNS health
75
Network security
100
GDPR outside view
88
Average
70

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen holds a leading market position in biotechnology with a focus on complex disease therapies. The Slovak website serves as a regional portal, linking to global and regional Biogen sites, indicating a broad partnership and operational ecosystem. The business model centers on research, development, and commercialization of specialty pharmaceuticals. The site targets healthcare professionals, patients, and stakeholders interested in Biogen's therapeutic areas. Growth indicators include active content updates, regional language support, and integration with global social media channels. The absence of direct contact emails or phone numbers suggests a preference for controlled communication via contact forms, enhancing data protection and compliance.

Security posture

The website employs HTTPS with secure cookie attributes and a comprehensive cookie consent mechanism, reflecting good privacy compliance. However, the lack of visible security headers such as Content-Security-Policy or X-Frame-Options represents an area for improvement. No incident response or vulnerability disclosure information is published, which could be a gap in transparency and readiness. No vulnerabilities or exposed sensitive data were detected in the HTML content. The security score is solid but could be elevated by publishing explicit security policies and implementing additional HTTP security headers.

Recommendations

  1. Implement and publish a dedicated security policy page including incident response contacts.
  2. Add HTTP security headers like Content-Security-Policy, X-Frame-Options, and X-XSS-Protection to enhance protection.
  3. Consider publishing a vulnerability disclosure policy or security.txt file to encourage responsible reporting.
  4. Enhance accessibility features to improve compliance with standards such as WCAG.
  5. Maintain and regularly audit third-party scripts and libraries to avoid vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen Slovakia s.r.o.
Description
Biogen je popredná celosvetová biotechnologická spoločnosť, ktorá je priekopníkom v oblasti vedy a prichádza s inováciami v liečbe komplexných a závažných ochorení. Spoločnosť Biogen rozvíja rad potenciálnych terapií v oblasti neurológie, neuropsychiatrie, špecializovanej imunológie a zriedkavých ochorení. Intenzívne sa sústreďuje na svoj cieľ prostredníctvom vedy prispieť k udržateľnosti zdravia pre všetkých.
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly cookies
  • Cookie consent with opt-in/out
  • Load balancing with AWSALB cookies

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and localized for Slovakia.
  2. Comprehensive cookie consent mechanism implemented with Cookiebot.
  3. Multiple language and regional versions linked.
  4. No direct email or phone contact found on homepage; contact form available.
  5. No explicit security or incident response policies published.
  6. Use of modern web technologies and Adobe Experience Manager CMS.
  7. Social media presence linked to official Biogen accounts.
  8. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on Adobe Experience Manager CMS, a robust enterprise platform suitable for large organizations. It uses modern JavaScript libraries including jQuery 3.6.4 and Adobe Helix RUM for performance monitoring. Cookiebot is integrated for cookie consent management, ensuring GDPR compliance. Google Tag Manager and Google Analytics are used for marketing and analytics purposes. The site is hosted likely on AWS infrastructure, indicated by AWSALB cookies. Performance is moderate with good mobile optimization and SEO practices. Some technical debt may exist due to reliance on older jQuery versions, but overall the technical stack is stable and enterprise-grade.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Earlier scans of this domain

  1. 81/100Low25 findingsView report
Reviews of this site

Share your experience with biogen.sk. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.sk.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.